SCM
IBER

Shaolin Capital Management’s Ibere Pharmaceuticals IBER Stock Holding History

Shaolin Capital Management’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-136,200
Closed -$1.34M – 1017
2022
Q2 		$1.34M Sell
136,200
-200,000
-59% -$1.96M 0.03% 450
2022
Q1 		$3.3M Hold
336,200
– – 0.08% 310
2021
Q4 		$3.27M Buy
+336,200
New +$3.27M 0.08% 309

Other funds holding IBER

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Shaolin Capital Management's IBER Position: Q3 2022 in Review

Shaolin Capital Management sold out of Ibere Pharmaceuticals (IBER) in Q3 2022, closing a stake of 136,200 shares — an estimated $1.34M sold.

Shaolin Capital Management first reported a position in IBER in Q4 2021 and held it in 3 quarters. The position peaked at $3.3M in Q1 2022. 48 funds tracked by Wall St. Rank hold IBER as of Q3 2022.

  • Shaolin Capital Management reported no remaining Ibere Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Shaolin Capital Management sold 136,200 Ibere Pharmaceuticals shares in Q3 2022, an estimated $1.34M.
  • Shaolin Capital Management first reported a position in Ibere Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Shaolin Capital Management's Ibere Pharmaceuticals position peaked at $3.3M in Q1 2022.
  • 48 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q3 2022.

Based on Shaolin Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.